Stocks · News reference
RenovoRx, Inc. has scheduled the release of its third quarter 2026 financial results and business highlights for after market close on November 5, 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
RenovoRx, Inc. announced that its CEO and CFO will present at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 11, 2026.
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared